A systematic review highlights threats to validity in studies of barriers to cancer trial participation

被引:91
作者
Fayter, Debra [1 ]
McDaid, Catriona [1 ]
Eastwood, Alison [1 ]
机构
[1] Univ York, Ctr Reviews & Disseminat, York YO10 5DD, N Yorkshire, England
关键词
systematic review; validity assessment; cancer; randomized controlled trials; barriers to participation; trial recruitment;
D O I
10.1016/j.jclinepi.2006.12.013
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: To investigate the barriers, modifiers, and benefits involved in participating in randomized controlled trials of cancer therapies as perceived by health care providers and patients. Study Design and Setting: We conducted a systematic review of the literature to identify published and unpublished studies in any language using electronic databases searched from 1996 to 2004, contact with experts, and reference lists. All study designs were acceptable provided relevant data were reported. Two reviewers were involved in the selection of studies, data extraction, and quality assessment processes. Studies were combined in a narrative synthesis. Results: Fifty-six studies met the inclusion criteria and represented the perspective of the patient or the health care provider or both. Although a range of barriers to trial participation were identified, a number of threats to the internal and external validity of the included studies limited interpretation of the evidence. Conclusion: The limitations within the evidence base do not permit a clear interpretation of the barriers, moderators, and benefits involved in participation in cancer trials. We recommend that trialists prospectively identify the issues relevant to a particular trial using the current research as a starting point. We report checklists to guide this process. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:990 / 1001
页数:12
相关论文
共 74 条
[1]   Barriers to the participation of African-American patients with cancer in clinical trials - A pilot study [J].
Advani, AS ;
Atkeson, B ;
Brown, CL ;
Peterson, BL ;
Fish, L ;
Johnson, JL ;
Gockerman, JP ;
Gautier, M .
CANCER, 2003, 97 (06) :1499-1506
[2]   Strategic physician communication and oncology clinical trials [J].
Albrecht, TL ;
Blanchard, C ;
Ruckdeschel, JC ;
Coovert, M ;
Strongbow, R .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3324-3332
[3]  
ALTMAN DG, 1991, CLIN TRIALS PRACTICA, P440
[4]   The ATAC (ArimidexTM, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients:: factors influencing the success of patient recruitment [J].
Baum, M .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (15) :1984-1986
[5]   Recruitment and retention of minority women in cancer screening, prevention, and treatment trials [J].
Brown, DR ;
Fouad, MN ;
Basen-Engquist, K ;
Tortolero-Luna, G .
ANNALS OF EPIDEMIOLOGY, 2000, 10 (08) :S13-S21
[6]  
BURNETT DB, 2001, ONCOL NURS FORUM, V28, P1187
[7]   Accrual issues for chemoprevention trials: The example of the 4-HPR study for the prevention of contralateral breast cancer [J].
Camerini, T ;
De Palo, G ;
Mariani, L ;
Marubini, E ;
Costa, A ;
Veronesi, U .
TUMORI JOURNAL, 1999, 85 (04) :299-303
[8]   Recruiting into palliative care trials: lessons learnt from a feasibility study [J].
Cook, AM ;
Finlay, IG ;
Butler-Keating, RJ .
PALLIATIVE MEDICINE, 2002, 16 (02) :163-165
[9]   Why patients don't take part in cancer clinical trials: an overview of the literature [J].
Cox, K ;
McGarry, J .
EUROPEAN JOURNAL OF CANCER CARE, 2003, 12 (02) :114-122
[10]  
Crombie I.K., 1996, POCKET GUIDE CRITICA